INO
Inovio Pharmaceuticals Inc
1.20$
+5.5%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 90.5% | 89.6% | 86.5% | 87.9% | 85.3% | 86.4% | 82.4% | 77.2% | 79.5% | 82.3% | 79.2% | 80.8% | |
| 9.7% | 8.4% | 15.2% | 25.7% | 20.3% | 58.1% | 45.7% | 35.7% | 52.7% | 59.6% | 52.8% | 63.8% | |
| 86.7% | 85.0% | 81.8% | 82.5% | 79.2% | 83.1% | 78.3% | 69.7% | 73.2% | 78.7% | 75.7% | 74.3% | |
| 1.1% | 1.4% | 2.0% | 1.3% | 1.7% | 1.1% | 1.5% | 1.2% | 1.4% | 0.0% | – | – | |
| – | – | – | – | 80,867.3% | – | – | – | – | – | – | – | |
| 7.6% | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | – | – | – | – | – | – | – | – | – | – | |
| 28.5% | 31.4% | 26.9% | 27.7% | 31.3% | 39.5% | 41.3% | 58.2% | 111.1% | 67.6% | 87.8% | 91.1% | |
| 22.6% | 24.9% | 18.1% | 19.7% | 21.9% | 31.2% | 31.3% | 46.5% | 100.6% | 58.8% | 76.2% | 80.8% | |
| 9.6% | 11.2% | 1.7% | 1.7% | 2.3% | 2.2% | 3.0% | 3.9% | 3.9% | 3.8% | 5.8% | 5.9% | |
| 2.0% | 2.7% | 6.4% | 4.8% | 5.0% | 5.7% | 6.3% | 8.0% | 8.5% | 3.5% | 4.0% | 23.6% | |
| 71.5% | 68.6% | 73.1% | 72.3% | 68.7% | 60.5% | 58.7% | 41.8% | -11.1% | 32.4% | 12.2% | 8.9% | |
| -827.5% | -949.4% | -1,280.6% | -1,259.9% | -1,598.0% | -1,528.5% | -2,005.1% | -2,598.8% | -2,621.5% | -2,442.7% | -3,686.1% | -3,727.2% | |
| 11.6% | 13.3% | 18.0% | 20.3% | 26.3% | 28.7% | 44.2% | 56.9% | 75.2% | 92.8% | 138.8% | 165.3% |
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.